Cell-Mediated and Humoral Immune Response to 2-Dose SARS-CoV2 mRNA vaccination in Immunocompromised patient population
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Characterization of cell-mediated and humoral immune responses to SARS-CoV2 mRNA vaccine has implications for protective immunity in immunocompromised patients. However, studies have demonstrated poor humoral response to SARS-CoV2 mRNA vaccine in immunocompromised patients and data on cellular immune response are currently lacking. Here we compared immune response after 2-dose vaccination in 100 immunocompromised patients (solid organ transplant recipients, hematologic malignancy, autoimmune condition, and primary immunodeficiency) and 16 immunocompetent healthy healthcare workers. We find that 100% (CI=80.6-100%) of immunocompetent individuals show positive cell-mediated and humoral immune response post vaccination while only 50% (CI=40.4-59.6%) of immunocompromised patients show humoral immune response and 69% (CI=59.4-77.2%) have a positive cell-mediated immune response. 21% of immunocompromised patients have no humoral immune response or cell-mediated immune response and thus are likely vulnerable to SARS-CoV2 infection. Monitoring of immune response in immunocompromised populations, particularly in high-risk immunocompromised patients (solid organ transplant recipients, patients with severe autoimmunity, and those ≥50 years), with clinical IGRA and serological assay after vaccination may identify patients who may benefit from revaccination or prophylactic monoclonal antibody therapy to prevent COVID-19 in this patient population
Article activity feed
-
SciScore for 10.1101/2021.07.21.21260921: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: Ethics: This study was approved by the Stanford University Institutional Review Board (IRB-60171 and IRB-57519).
Consent: Healthcare worker participants provided informed consent to donate blood samples via venipuncture after second dose of vaccination with BNT162b2. IGRA and IgG ELISA were ordered in immunocompromised patients by their providers as part of clinical testing.Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
Software and Algorithms Sentences Resources Statistics: GraphPad Prism version 9.0 (GraphPad Software, San Diego, California, USA) software was used to visualize data and Mann-Whitney U … SciScore for 10.1101/2021.07.21.21260921: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: Ethics: This study was approved by the Stanford University Institutional Review Board (IRB-60171 and IRB-57519).
Consent: Healthcare worker participants provided informed consent to donate blood samples via venipuncture after second dose of vaccination with BNT162b2. IGRA and IgG ELISA were ordered in immunocompromised patients by their providers as part of clinical testing.Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
Software and Algorithms Sentences Resources Statistics: GraphPad Prism version 9.0 (GraphPad Software, San Diego, California, USA) software was used to visualize data and Mann-Whitney U test was performed to compare cellular and humoral response in immunocompetent and immunocompromised patients. Statistics: GraphPad Prismsuggested: NoneGraphPadsuggested: (GraphPad Prism, RRID:SCR_002798)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-